Guizhou bailing Enterprise Group Pharmaceutical Co., Ltd. (002424)

Guizhou bailing Enterprise Group Pharmaceutical Co., Ltd. (002424)

Guizhou bailing Enterprise Group Pharmaceutical Co., Ltd. (hereinafter referred to as "Guizhou bailing") is a listed pharmaceutical company engaged in R & D, production and sales of Miao medicine, with a registered capital of 1.4112 billion yuan, total assets of 7.059 billion yuan and 5961 employees. In June 2010, the company was successfully listed on Shenzhen Stock Exchange (Stock Code: SZ 002424). The company clearly focuses on the strategic development goal of "strengthening the company's dominant position in the field of Miao medicine, striving to become an enterprise with core competitive advantage in the field of Chinese patent medicine", takes the implementation of "scientific and technological Miao medicine, cultural Miao medicine and ecological Miao medicine" as the starting point, and is committed to building an enterprise group with a large and healthy whole industry chain.

After more than 20 years of development, the company continues to increase investment in brand building while expanding its scale, so as to enhance its brand awareness and market influence. After years of development, the company has formed a strong product structure and brand system led by "bailingniao" brand cardio cerebrovascular drugs Yindanxinnaotong soft capsules, cold and cough drugs vitamin C Yinqiao Tablets, kesutong syrup and capsules, Jinggan capsules, Xiaoer chaigui Tuire granules, gynecological drugs Kangfuling capsules, jingdaning capsules and other traditional Chinese medicine and Miao medicine.

The company's main varieties are Yindanxinnaotong soft capsule, Xiaoer chaigui Tuire granule, qianglipipa dew, motherwort ointment, Huanglian Shangqing tablet, Niuhuang Jiedu tablet, Yiqing granule, etc. 36 varieties and 54 approval documents are included in the national essential medicine catalogue (2018 Edition). Among them, Yindanxinnaotong soft capsule is the exclusive variety in China, and Xiaoer chaigui Tuire granule is a new one, For the national exclusive specifications. A total of 51 varieties of the company's products, such as Yindanxinnaotong soft capsule, Xiaoer chaigui Tuire granule, vitamin C Yinqiao tablet, and bilinqing capsule, have been included in the medical insurance catalogue (2019 Edition).

China over the counter drug association released the "list of China's over the counter drug enterprises and products in 2019". With its comprehensive strength and unique advantages, Guizhou bailing won the 16th place in the top 100 OTC manufacturers in China in 2019, which was steadily improved compared with the previous year; At the same time, Guizhou bailing cough syrup / capsule, vitamin C Yinqiao Tablets, pediatric Chai Gui antipyretic granule, compound Huanghua spray, Shuangyang laryngton granule and other 8 varieties, ranking the forefront of all categories of products.

The company has always attached great importance to product R & D and regarded it as the driving force to promote its own development. It has established a relatively perfect technological innovation system.

The company has won the honors of national recognized enterprise technology center, national innovative enterprise, National Torch Plan key high-tech enterprise, national technological innovation demonstration enterprise, national intellectual property advantage enterprise, Guizhou innovative leading enterprise cultivation enterprise, Guizhou intellectual property advantage enterprise, etc, At the same time, the national and local joint engineering research center of modern Miao medicine innovation technology, National Postdoctoral research workstation, academician workstation, Guizhou provincial engineering technology research center of ethnic medicine (traditional Chinese Medicine) compound preparation, Guizhou southwest ethnic medicine (traditional Chinese Medicine) oral preparation manufacturing technology industry university research cooperation innovation alliance, modern Miao Medicine Innovation Technology Research Institute and other R & D platforms have been established.

By combining the resources of scientific research institutes, universities and enterprises in "production, learning, research and application", we have continuously enhanced the company's core competitiveness in drug research and development, actively explored the new mode and mechanism of school enterprise cooperation and collaborative innovation, promoted independent technological innovation, promoted the transformation of scientific and technological achievements, accelerated the cultivation of high-level talents of the company, and met the needs of talent reserve of the company, Further consolidate and enhance the core competitiveness of the company.

In 2019, the company obtained 15 patents, including 7 PCTs, 1 domestic invention patent, 5 utility model patents and 2 appearance designs. At present, the company has 101 valid patents, including 7 PCTs, 61 domestic inventions, 7 designs and 26 utility models. The company's 17 varieties of Miao medicine all have invention patents.

Guizhou bailing closely follows the "healthy China" strategy, adheres to the enterprise concept of "specializing in medicine and focusing on people", centers on the strategic goal of building a well-off society in an all-round way, takes improving the health of the whole people as its own responsibility, adheres to relying on mature brands and taking advantageous varieties as the core, and constantly strengthens the construction of R & D innovation system and R & D investment, so as to realize the sustainable development of the company.

In the future, the company will continue to take national medicine and Miao medicine as the core, chemical medicine and biological medicine as the two wings of the development strategy, and strive to build an enterprise group with a large health industry chain.

>> electrical submersible pump manufacturers esp pump cable manufacturer